TargetMol

BMS-536924

Product Code:
 
TAR-T6419
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6419-1mg1mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6419-5mg5mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6419-1mL1 mL * 10 mM (in DMSO)£133.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6419-10mg10mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6419-25mg25mg£278.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6419-50mg50mg£468.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6419-100mg100mg£603.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
CAS:
468740-43-4
Formula:
C25H26ClN5O3
Molecular Weight:
479.97
Pathway:
Cytoskeletal Signaling; Apoptosis; Tyrosine Kinase/Adaptors; MAPK; Angiogenesis
Purity:
0.9919
SMILES:
Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1
Target:
Apoptosis; FAK; MEK; IGF-1R; Src

References

Litzenburger BC, et al. Clin Cancer Res, 2009, 15(1), 226-237 Wittman M, et al. J Med Chem, 2005, 48(18), 5639-5643 Hirokazu Ohashi, et al. Cancer Sci, 2012, 103(2), 252-261 Huang F, et al. Cancer Res, 2009, 69(1), 161-170 Haluska P, et al, Mol Cancer THer, 2008, 7(9), 2589-2598.